Abstract
A reliable, widely available method to detect osteoporosis prior to fracture is needed. Serum levels of C-reactive protein may independently predict low bone mineral density (BMD) and high fracture risk. Existing empirical data focus on sexually and/or racially homogenous populations. This study tests the hypotheses that: C-reactive protein (1) negatively correlates with BMD and (2) fracture history, and (3) independently predicts BMD and fracture history in a diverse population. NHANES 2017-2020 pre-pandemic cycle data were analyzed in R studio. Strength and direction of relationships (-1 to +1) between variables were determined using Kendall’s rank correlation coefficient (τ). Linear models were optimized to predict femoral neck or lumbar spine BMD. C-reactive protein positively correlated with femoral (τ=0.09, p<0.0001) and spine BMD (τ=0.10, p<0.0001). Individuals identifying as female demonstrated more robust, but still weak, correlations between C-reactive protein and femoral neck (τ=0.15, p<0.0001; male, τ=0.06, p=0.051) and spine BMD (τ=0.16, p<0.0001; male, τ=0.06, p=0.04). C-reactive protein positively correlated with fracture history (τ=0.083, p=0.0009). C-reactive protein significantly predicted femoral neck (R2=0.022, p=0.0001) and spine BMD (R2=0.028, p<0.0001) and fracture history (R2=0.015, p<0.0001). Exploratory analyses identified weight was the single best predictor for femoral neck (R2=0.24, p<0.0001) and spine BMD (R2=0.21, p<0.0001). In sum, C-reactive protein statistically correlates with and predicts femoral neck and spine BMD, but the magnitude is too low to be biologically meaningful. While weight is a more robust predictor, individuals who are overweight or obese account for nearly half of all osteoporotic fractures, limiting the predictive power of this variable at identifying individuals at risk for osteoporosis. Identification of a robust predictor of fracture risk in a diverse population and across of range of body weights and compositions is needed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human research conducted by the US government (NHANES).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data files are publicly available on the CDC website listed under the NHANES 2017-2020 Pre-pandemic Dataset (https://www.n.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?Cycle=2017-2020).
https://www.n.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?Cycle=2017-2020
